Qiu Bo Sun
Director/Board Member at Beijing Xiangxin Biotechnology Co., Ltd.
Profile
Qiu Bo Sun has worked as a Member-Supervisory Board at Beijing Xiangxin Biotechnology Co., Ltd.
since 2019.
Qiu Bo Sun active positions
Companies | Position | Start |
---|---|---|
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Director/Board Member | 2019-03-06 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Health Technology |
- Stock Market
- Insiders
- Qiu Bo Sun